Home > Insider Trading > Filing (0000899243-20-024201)

Filing Details

Accession Number:: 0000899243-20-024201
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-03 21:21:25
Reporting Period:: 2020-09-01

Accepted Time:: 2020-09-03 21:21:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1354345	Phd J Bradley Bolzon	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-09-01	30,000	$14.00	30,000	No	4	M	Indirect	See Footnote
Common Shares	Acquisiton	2020-09-01	15,000	$13.62	45,000	No	4	M	Indirect	See Footnote
Common Shares	Acquisiton	2020-09-01	15,000	$59.31	60,000	No	4	M	Indirect	See Footnote
Common Shares	Disposition	2020-09-01	4,300	$91.27	55,700	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2020-09-01	36,365	$92.40	19,335	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2020-09-01	19,135	$92.98	200	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2020-09-01	200	$93.74	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See Footnote
No	4	M	Indirect	See Footnote
No	4	M	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2020-09-01	30,000	$0.00	30,000	$14.00
Common Shares	Stock Option (Right to Buy)	Disposition	2020-09-01	15,000	$0.00	15,000	$13.62
Common Shares	Stock Option (Right to Buy)	Disposition	2020-09-01	15,000	$0.00	15,000	$59.31

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
30,000	2026-10-18	No	4	M	Indirect
15,000	2027-05-31	No	4	M	Indirect
15,000	2028-06-15	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	554,190	Indirect	See Footnote
Common Shares	1,192,139	Indirect	See Footnote
Common Shares	34,977	Indirect	See Footnote
Common Shares	38,772	Indirect	See Footnote
Common Shares	90,730	Indirect	See Footnote
Common Shares	2,238,979	Indirect	See Footnote
Common Shares	13,277	Indirect	See Footnote

Footnotes

These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.73 to $91.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.73 to $92.725, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.73 to $93.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
This option was granted on October 18, 2016 with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
This option was granted on May 31, 2017 with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017.
This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018.